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Abstract
Sphingomyelin synthases (SMS1 and 2) represent a class of enzymes that transfer a phosphocholine moiety from
phosphatidylcholine onto ceramide thus producing sphingomyelin and diacylglycerol (DAG). SMS1 localizes at the Golgi
while SMS2 localizes both at the Golgi and the plasma membrane. Previous studies from our laboratory showed that
modulation of SMS1 and, to a lesser extent, of SMS2 affected the formation of DAG at the Golgi apparatus. As a
consequence, down-regulation of SMS1 and SMS2 reduced the localization of the DAG-binding protein, protein kinase D
(PKD), to the Golgi. Since PKD recruitment to the Golgi has been implicated in cellular secretion through the trans golgi
network (TGN), the effect of down-regulation of SMSs on TGN-to-plasma membrane trafficking was studied. Down
regulation of either SMS1 or SMS2 significantly retarded trafficking of the reporter protein vesicular stomatitis virus G protein
tagged with GFP (VSVG-GFP) from the TGN to the cell surface. Inhibition of SMSs also induced tubular protrusions from the
trans Golgi network reminiscent of inhibited TGN membrane fission. Since a recent study demonstrated the requirement of
PKD activity for insulin secretion in beta cells, we tested the function of SMS in this model. Inhibition of SMS significantly
reduced insulin secretion in rat INS-1 cells. Taken together these results provide the first direct evidence that both enzymes
(SMS1 and 2) are capable of regulating TGN-mediated protein trafficking and secretion, functions that are compatible with
PKD being a down-stream target for SMSs in the Golgi.
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Introduction
Sphingomyelin synthase (SMS), also known as phosphatidyl-
choline:ceramide cholinephosphotransferase, is the last enzyme in
the sphingomyelin (SM) synthetic pathway. It synthesizes SM by
transferring the phosphorylcholine moiety from phosphatidylcho-
line (PC) onto ceramide, thus producing not only SM but also
diacylglycerol (DAG) [1,2]. The mammalian SMS family is
composed of two members (namely SMS1 and SMS2) that use
the same reaction chemistry and are encoded by two distinct genes
[3,4]. Thus far, only few features that differentiate SMS1 and
SMS2 have been identified. First, the specific ability of SMS2 to
use phosphatidylethanolamine (PE) as head group donor in
addition to PC [5]; second, the presence of a sterile alpha motif
at the N-terminus of SMS1 (absent in SMS2), whose function
remains unknown [6]; and third, their subcellular localization
[3,6,7,8]. In fact, SMS1 is localized at the Golgi apparatus
whereas SMS2 is localized at the Golgi and plasma membrane by
virtue of S-palmitoylation at the COOH terminus [7].
Given the biochemical reaction modulated by SMSs, three
features have been considered as potential platforms for a critical
role of these enzymes in the regulation of cellular functions: the
production of SM, a key phospholipid for the maintenance of lipid
raft integrity [9,10,11,12]; the regulation of ceramide, a bioactive
lipid often involved in the control of cell proliferation, differen-
tiation, apoptosis and inflammation (for a review see
[13,14,15,16,17]); and the modulation of DAG, a well-established
mitogenic lipid also involved in other cellular processes, such as
vesicular trafficking [18,19].
Indeed regulation of SM, ceramide, and DAG has been
documented upon modulation of either SMS1 or SMS2 by gene
over-expression, by their down-regulation using siRNA or by the
use of knock-out animals in the case of SMS2. The role of SMS1
in maintenance of lipid microdomain structure and function via
modulation of SM levels has been shown in response to Fas
ligation, treatment with alkyl-lysophospholipids and CD3
[10,11,20]. Similarly, involvement of SMS2 has been demonstrat-
ed by using macrophages from SMS2 KO mice treated with
lypopolysaccharide or in HEK 293 or THP-1 derived macro-
phages upon siRNA-mediated down-regulation and treatment
with tumor necrosis factor a (TNF-a) [21]. On the other hand,
over-expression of SMS1 or SMS2 in Chinese hamster ovary
(CHO) cells promoted the formation of detergent-insoluble
microdomains and apoptosis induced by TNF [21]. Changes in
ceramide levels due to modulation of SMSs might be differently
regulated depending on the specific cellular context. In fact, in
resting Jurkat and CHO cells over-expression of SMS1 or SMS2
caused an increase of ceramide as part of a general stimulation of
sphingolipid synthesis [22] whereas, in Jurkat cells, it prevented
accumulation of ceramide in response to photodamage [22]. On
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down regulation of SMS1 or SMS2 enhanced accumulation of
ceramide [8,23,24,25].
Regulation of DAG by SMSs has been quite elusive
[8,21,24,25]. The best characterized cell model for such regulation
is represented by HeLa cells, upon stimulation of SMSs activity at
the Golgi. Using this model, we previously demonstrated that
DAG is produced in this organelle by both SMS1 and SMS2, and
we preliminarily proposed the DAG-binding protein, PKD as
binding partner of this specific pool of DAG [8].
PKD constitutes a family of serine/threonine-specific kinases
that in mammalian cells is composed of three closely related
isoforms, PKD1/PKCm [26], PKD2 [27]and PKD3/PKCn [28].
Activation of PKD at the Golgi occurs after translocation of the
kinase to this organelle where its C1 domain binds to DAG
[29,30,31,32]. Activated PKD at the Golgi has been shown to
promote vesicular fission from the trans golgi network (TGN) [33].
Thus far, formation of DAG at the Golgi is thought to be a
consequence of the activation of phospholipase C b3 by the
heterotrimeric G protein bc subunits (Gbc) [34]. In addition to
DAG, recruitment of PKD at the Golgi may also be facilitated by
binding of Gbc to the pleckstrin homology (PH) domain [35] of
PKD. The production of DAG at the Golgi also favors the
translocation of PKCg, which in turn is activated by Gbc.
Activated PKCg at the Golgi phosphorylates the kinase activation
loop domain of PKD at Serines 744–748 and relieves the
inhibition of PKD by its own PH domain [36]. Once activated
in the Golgi complex, PKD phosphorylates PI4KIIIb and the
ceramide transfer protein (CERT). PI4KIIIb promotes formation
of PI(4)P [37] which binds to CERT via its PH domain, recruiting
CERT to the Golgi apparatus. CERT facilitates transport of
ceramide from the ER to the Golgi for SM synthesis by SMS [38],
and phosphorylation of CERT by PKD at the Golgi diminishes
CERT’s affinity for PI(4)P [39]. Based on these observations,
phosphorylation of CERT by PKD is thought to exert a negative
feedback on SMS-dependent PKD activation, even though no
direct evidence for a role of SMS-derived DAG on the function of
endogenous PKD is available in the literature. Finally, active PKD
also phosphorylates oxysterol-binding protein (OSBP) which is also
recruited to the Golgi via PI(4)P. Phosphorylation of OSBP by
PKD was found to impair the Golgi localization of OSBP in
response to 25-hydroxycholesterol. This in turn affected CERT
localization at the Golgi and provided an additional level of
regulation to this tightly controlled multistep process [40].
Thus, in order to investigate whether SMS1 and SMS2 regulate
TGN functions in a fashion that is compatible with the potential
role of PKD as down-stream target of SMSs, we studied the role of
SMSs in the vesicular trafficking from the Golgi to the plasma
membrane. Here we report that inhibition of SMS1 or SMS2
alters the structure of the Golgi apparatus in a way similar to
inhibition of PKD, and that inhibition of SMS1 or SMS2 impairs
protein transport from the TGN to the plasma membrane and
secretion of an endogenous cargo like insulin. Implications of these
findings are discussed.
Materials and Methods
Materials
DMEM (Dulbecco’s modified Eagle’s medium), RPMI 1640
medium, Opti-MEM, trypsin/EDTA solution, FBS (fetal bovine
serum) and Penicillin/Streptomycin solution were from Gibco/
Invitrogen. Bradford protein assay kit was from BioRad (Cat No:
500-0006). RIA and ELISA kits were from Millipore (Cat. No: RI-
13K and EZRMI-13K, respectively).
Cell culture
Exponentially growing HeLa cells (obtained from the American
Type Culture Collection) not exceeding 20 passages were cultured
in high glucose DMEM. The medium was supplemented with
10%FBS, 1% Penicillin/streptomycin solution and cells were
grown at 37uC in a humidified 5% CO2 incubator. The rat INS-1
(823/13) cells were a generous gift from Drs. Buse and Lemasters
(Medical University of South Carolina, SC, USA) and Dr.
Newgard (Gifford Laboratories for Diabetes Research, University
of Texas Southwestern Medical center, Dallas, TX, USA). These
cells were cultured in RPMI-1640 medium containing 11.1 mM
glucose, 10%FBS, 1%Penicillin/streptomycin solution, 10 mM
HEPES, 2 mM L-glutamine, 1 mM sodium-pyruvate and
0.05 mM 2-mercaptoetanol at 37uC in a humidified 5% CO2
incubator, and they were used between 76 and 92 population
doublings (PDs).
Down regulation of SMS1 and SMS2
Down regulation of human SMS1 or SMS2 in Hela cells was
achieved with siRNA oligonucleotides targeting SMS1: CTA-
CACTCCCAGTACCTGG (SMS1.3 siRNA) and CACAC-
TATGGCCAATCAGCAA (SMS1.4 siRNA), or SMS2: AACC-
CAAGAGCTTATCCAGTG (SMS2.2 siRNA), and ACCGTC-
ATGATCACAGTTGTA (SMS2.3 siRNA) synthesized by Qia-
gen, and by using Oligofectamine
TM transfection reagent
(Invitrogen). The non-specific All Star siRNA sequence from
Qiagen (SCR; scrambled siRNA) was used as control. HeLa cells
were plated in 35 mm diameter confocal dishes at a density of
4610
4 per plate. After 24 hours, cells were transfected with siRNA
according to the manufacturer’s instructions in a total volume of
1 ml of transfection mixture containing siRNA and Oligofectami-
ne
TM in Optimem medium (148 ng of SiRNA). After 6 hours of
incubation, 1 ml of DMEM containing 20% FBS was added to the
plates. In Hela cells, SMS1 down-regulation with either siRNA
sequence results in more than 70% decrease of mRNA expression
and 50–60% reduction of total SMS activity whereas SMS2 down-
regulation with either siRNA sequence results in more than 70%
decrease of mRNA expression and 30–40% reduction of total
SMS activity. Neither one of the siRNA sequences for one SMS
affects the expression of the other isoform [8,25] (and data not
shown).
Down-regulation of rat SMS1 or SMS2 in INS-1 (832/13) was
achieved using Stealth siRNA oligonucleotide targeting SMS1:
GGGCAAGACTTTGCTGGCCTTTCTT (Rat SMS1.1 siRNA)
and CCTGTACCGGTGTATTACAATGTAT (Rat SMS1.2
siRNA), or SMS2: TGGCTCTTTCTGAGATACAAGTCAA
(Rat SMS2.1 siRNA) and CAGTTGTGCTGA CACTTACT-
TACTT (Rat SMS2.2 siRNA) synthesized by Invitrogen, and by
using Lipofectamine 2000 transfection reagent (Invitrogen). A non-
specific negative control siRNA sequence from Invitrogen (SCR
siRNA; scrambled siRNA) was used as control. Cells were either
treated with a concentration of 50 nM of each individual siRNA
sequence or with a combination of 50 nM of each siRNA sequence
targeting the samegene.Inthe lattercase,100 nMSCRsiRNA was
used as control (SCR siRNA mix). These siRNA concentrations
were found to exert the strongest down-regulation of rat SMS1 and
SMS2. Rat INS-1 (832/13) cells were plated in 12-wells plates at a
density of 3610
5 cells/well. After 24 hours, cells were transfected
with siRNA according to the manufacturer’s instructions. After
27 hrs from transfection, medium was replaced with 1 ml of fresh
complete medium (RPMI medium containing 5 mM glucose, 10%
FBS and 1% Penicilin/streptomycin solution, 10 mM HEPES,
2 mM L-glutamine, 1 mM sodium-pyruvate and 0.05 mM 2-
mercaptoethanol). After 18 hours, cells were washed in 1 ml HBSS
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MgSO4, 20 mM HEPES, 2.5 mM CaCl2, 25.5 mM NaHCO3
and bovine serum albumin (essentially fatty acid free), pH 7.2]
containing 3 mM glucose followed by 2 hours incubation in 2 ml of
the same buffer (47 hours from transfection). Cells were then
collected and frozen at 280uC for RT-PCR or treated for
measurements of insulin secretion as described below.
Real-time (RT)-PCR
T o t a lR N Af r o mH e l ao rI N S - 1c e l l sw a se x t r a c t e du s i n ga nR N e a s y
Mini Kit (Qiagen) following the manufacturer’s suggested protocol
(including the optional DNase and wash steps). The general protocol
for RT-PCR for SMS1 and SMS2 was performed as indicated by
Villani et al [8]. The results were normalized to an internal control
gene, beta actin. The RT-PCR results were analyzed using Q-GeneH
software, which expresses data as the means of normalized expression.
The primers were designed using PerkinElmer Primer ExpressH
software. Primer sequences for human SMS1 and SMS2 are described
in Villani et al [8] whereas primer sequences for rat SMS1 and SMS2
are as follows: beta Actin,f o r w a r d :5 9-GCTACAGCTTCACCAC-
CACA-39, reverse: 59-TCTCCAGGGAGGAAGAGGAT-39; SMS1,
forward: 59-TCACAGGCCAGGACCTAATC-39,r e v e r s e :5 9-
TGCTCCATCTTCAGGGTCTC-39; SMS2,f o r w a r d :5 9-AGCCC-
CACTGAAGCTGTAGA-39, reverse: 59-CCACTCTAGGGGAA-
GCTTGTT-39.
Immunofluorescence and confocal microscopy
HeLa cells were plated in 35 mm diameter confocal dishes at a
density of 4610
4 cells/plate (in 2 ml of 10% FBS containing
DMEM medium). After 48 hours, medium was replaced with 1 ml
of fresh DMEM containing 10% FBS. In case of treatment with
pharmacological inhibitors, 10 to 50 mg/ml of the SMS inhibitor
D609 (Enzo Life sciences, Cat. No: ST-330) or 10 to 40 mM of the
protein kinase D (PKD) inhibitor CID755673 (TOCRIS Biosci-
ences, Cat.No:3327) were added to the plates and incubated for
4 hours. For down-regulation of SMSs, cells were plated at a
density of 3610
4 per plate in 35 mm diameter confocal dishes.
After 24 hours, cells were transfected as described above with
148 ng SCR, SMS1.4 or SMS2.3 siRNA for 48 hours. Treated
cells (both after pharmacological treatment or siRNA-mediated
down-regulation) were fixed with 3.7% formaldehyde for 15 min
at room temperature (24uC). After washing the plates with PBS,
cells were permeabilized with 100% methanol (220uC) for 5 min.
Cells were washed with 1.5% FBS in PBS for 5 min and then
blocked with 2.5% FBS in PBS for 1 hour at room temperature.
Incubation with the primary antibody was performed using 1:50
dilution of rabbit anti-human TGN 46 antibodies (from Novus
Biological, Cat. No: NB110-40769) or Polyclonal rabbit antibodies
against GPP130 (Covance, Cat No: PRB-144C), in 1.5% FBS in
PBS containing 0.5% saponin for 3 hours at room temperature or
overnight at 4uC. Cells were then washed three times with 1.5%
FBS/PBS for 5 min each and incubated with anti-rabbit Alexa
FluorH 488 (1:400 dilution in PBS containing 1.5% FBS and 0.5%
Saponin) for 1 hour at room temperature, in the dark. Cells were
washed three times with 1.5% FBS/PBS for 5 min each before
analysis at the confocal microscope. Confocal images were
captured and processed using an LSM 510 META laser-scanning
microscope (Zeiss, Jena Germany).
INS-1 cells were plated in 35 mm confocal dishes at a density of
1610
5 cells/plate and were grown to 100% confluence. The
standard tissue culture medium containing 11.1 mM glucose was
then replaced by 1 ml of fresh medium containing 5 mM glucose.
After 14 hours, cells were treated for 4 hours with the SMS
inhibitor, D609 (10 to 50 mg/ml), or the PKD inhibitor
CID755673 (10 to 40 mM) while control cells received sterile
water or DMSO (0.05%), respectively. Cells were fixed and
processed for confocal microscopy as described for HeLa cells.
Cells were co-stained with rabbit polyclonal anti-GPP130
(Covance) and purified mouse monoclonal anti-rat TGN38 (from
BD Transduction Laboratories, Cat No: 610898) (1:50 dilution).
Plates were processed as indicated above, with the exception that
anti-rabbit Alexa FluorH 488 and anti-mouse Alexa FluorH555
(1:400 dilution in PBS containing 1.5% FBS and 0.5% Saponin)
were used. Series of scans along the Z axis were taken by confocal
microscopy and analyzed by velocity 3 software (Improvision).
VSVG-GFP transport assay
A temperature-sensitive mutant of vesicular stomatitis virus G
protein tagged with GFP (VSVG-GFP), kindly provided by Dr. Kai
Simons [European Molecular Biology Laboratory (EMBL), Meyer-
hofstrasse 1, 69117 Heidelberg, Germany], was used to study
plasma membrane transport by following the procedure described
by Toomre et al., [41] with slight modifications. HeLa cells were
plated in 35 mm diameter confocal dishes at a density of 5610
4
cells/plate (2 ml of DMEM containing 10% FBS). After 48 hours,
cells were transfected with 2 mg of VSVG-GFP plasmid using
Lipofectamine 2000 (Invitrogen, Cat no: 11668-019) and incubated
at 37uC overnight. Then medium was replaced with fresh DMEM
containing 10% FBS and 0.1 M HEPES (pH 7.4) and the plates
were shifted to 40uC (temperature at which VSVG-GFP reversibly
misfolds and stays in the ER) for five and half hours (Figure S1).
After incubation, the medium was replaced by DMEM containing
10% FBS, 0.1 M HEPES pH 7.4 and 100 mg/ml of cyclohexamide
(to stop newly synthesized protein) and plates were shifted to 32uC
(temperature at which VSVG-GFP folds correctly and exits the ER
en-route to the Golgi apparatus [42]). After 30 min at 32uC,
VSVG-GFP reached the Golgi complex (Figure S1) and within
60 min it slowly reached the plasma membrane (Figure S1).
Beyond 60 minutes, (65 and 70 min) endocytosis of VSVG-GFP
was observed in agreement with previous studies [41]. Thus for the
studies of the role of SMSs on the trafficking of VSV-GFP to the
plasma membrane, 60 min incubation at 32uC was selected. For
down-regulation of SMSs, cells were plated at a density of 3610
4
per plate in 35 mm diameter confocal dishes. After 24 hours, cells
were treated with 148 ng of SCR, SMS1.3, SMS1.4 or SMS2.2,
SMS2.3 siRNA or Oligofectamine
TM alone (control). After
48 hours of down-regulation, cells were transfected with 2 mgo f
VSVG-GFP by using Lipofectamine 2000 and they were incubated
overnight at 37uC and processed as indicated above. After the five
and half hours incubation at 40uC and 1 hour at 32uC, cells were
fixed with 3.7% formaldehyde for 15 min at room temperature
(24uC). After washing the plates with PBS, the cells were analyzed
by confocal microscopy.
For specific detection of plasma membrane VSVG-GFP,
monoclonal 8G5F11 antibodies that recognize the extracellular
domain of VSVG (kindly provided by Dr. Douglas S. Lyles, Wake
Forest University Baptist Medical Center, NC) were used in fixed
(non-permeabilized) cells [43]. After fixation, cells were washed
once with 1.5% FBS in PBS for 5 min as described above, and
incubation with the 8G5F11 primary antibodies was performed in
1.5% FBS in PBS at 1:50 dilution for 3 hours at room temperature
or overnight at 4uC. Cells were washed three times with 1.5% FBS
in PBS for 5 min each and incubated with anti-mouse Alexa
FlourH 555 conjugated antibodies (1:400 in 1.5% FBS in PBS) for
1 hour at room temperature in the dark. Cells were washed three
additional times with 1.5% FBS/PBS for 5 min each before
analysis at the LSM 510 META laser-scanning microscope (Zeiss,
Jena Germany).
Role of SMSs in Protein Trafficking and Secretion
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For insulin secretion assays the protocol by Hohmeier et al., [44]
with slight modifications was employed. For pharmacological
inhibition of SMSs and PKD, rat INS-1 (832/13) cells were plated
onto 24-wells plates at a density of 3610
5 cells/well and were
grown to 100% confluence before assay. The standard tissue
culture medium containing 11.1 mM glucose was then replaced by
1 ml of fresh medium containing 5 mM glucose. After 14 hours
cells were treated for 4 hours with the SMS inhibitor, D609
(30 mg/ml and 50 mg/ml), or the PKD inhibitor CID755673
(20 mM and 40 mM) while control cells received sterile water or
DMSO (0.05%), respectively. Cells were washed in 1 ml HBSS
(114 mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 1.16 mM
MgSO4, 20 mM HEPES, 2.5 mM CaCl2, 25.5 mM NaHCO3
and bovine serum albumin [essentially fatty acid free], pH 7.2)
containing 3 mM glucose followed by a 2 hours pre-incubation in
2 ml of the same buffer. For siRNA-mediated down-regulation of
SMS1 or SMS2, cells were plated and treated as described for INS-
1 cells in the paragraph ‘‘down-regulation of SMS1 or SMS2’’.
After the 2 hours incubation in HBSS medium containing 3 mM
glucose, the buffer was replaced with 0.8 ml of HBSS containing
different concentrations of glucose (3 mM or 8 mM). After 2 hours
of static incubation, the medium was collected and spun at 4006g,
5 min at 4uC. Supernatant was then used for measuring secreted
insulin. Cells were then collected by gently dislodging them from
the plates using a cell lifter in the presence of ice-cold HBSS
(600 ml) without glucose. Detached cells were combined with
pelleted cells from medium, and spun down at 4006g, 5 min at
4uC. Pellets were sonicated in 1 M acetic acid containing 0.1%
bovine serum albumin and aliquots were used to determine
cellular insulin. Insulin measurements from experiments with
pharmacological inhibitors were performed by radioimmunoassay
(RIA) whereas insulin from siRNA-mediated down-regulation
experiments was determined by ELISA. Both RIA and ELISA
measurements were performed using rat insulin kits from Millipore
and the procedure followed the manufacturer’s guide.
In both cases, total insulin content was calculated as cellular plus
secreted insulin, and secreted insulin was calculated as percent
versus total. Since the percent of secretion in basal conditions
(3 mM glucose) was variable, final representation of glucose-
stimulated secreted insulin is given as fold change relative to
insulin secreted in basal conditions (3 mM glucose).
Statistical analysis
Statistical analysis of the data was performed using student’s two
tailed t-test and P,0.05 was considered statistically significant.
Results and Discussion
Modulation of SMS affects the organization of the Golgi
in HeLa cells
Since we previously provided direct evidence that both SMS1
and SMS2 possessed the ability of regulating production of DAG at
the Golgi and that this pool of DAG is biologically active for
recruitment of over-expressed PKD from the cytosol to the Golgi,
we hypothesized that PKD might be a downstream target for SMS1
and SMS2 at the Golgi. If this is true, then inhibition of SMSs
should induce morphological changes of the Golgi structure similar
to those evoked by inhibitionof PKD activity. Since PKD activity at
the Golgi is required for fission of secretory vesicles from the TGN,
inhibition of PKD has been shown to induce tubulation of the TGN
[35,45]. In agreement with thesepublished observations, incubation
of HeLa cells with the PKD inhibitor CID755673 (20 mM) induced
tubulation (in ,70% of the cells) of the TGN assessed by staining
with the TGN46 marker (Figure 1, panels B and B1)a s
compared to the intact organization of the TGN in control cells
Figure 1. Pharmacological inhibition of SMS causes extensive tubulation of the TGN. HeLa cells were treated with DMSO (control for PKD
inhibitor) (1A) or water (control for SMS inhibitor) (1C), and 20 mM of PKD inhibitor (1B) or 30 mg/ml of SMS inhibitor D609 (1D). After 4 hours of
incubation, cells were fixed and processed for indirect Immunofluorescence with anti TGN 46 (trans golgi marker) rabbit polyclonal antibodies and
stained with anti rabbit Alexa FluorH 488-conjugated secondary antibodies. Confocal images were captured and processed using an LSM 510 META.
Images are representatives of at least three independent experiments. Dashed boxes outline the areas that were magnified.
doi:10.1371/journal.pone.0023644.g001
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of the cells was observed (data not shown). Similarly to inhibition of
PKD, pharmacological inhibition of SMS activity by D609 (20 mg/
ml and 30 mg/ml) also induced significant tubulation of the TGN
(,40% and 60–70% of the cells, respectively) (Figures 1, panels
D and D1 for 30 mg/ml D609). To ensure the specificity of the
results and to determine if both SMSs are involved in maintenance
of the Golgi morphology (since D609 inhibits both SMS1 and
SMS2, [24,46,47]), the effect of siRNA-mediated down-regulation
of either SMS on TGN structure was determined (Figure 2).
Validated siRNA sequences were used [8,25], along with a siRNA
scrambled control (AllStar, Quiagen). Cells treated with either
SMS1 (Figure 2B) or SMS2 (Figure 2C) siRNA showed tubular
protrusions from the TGN reminiscent of inhibited vesicle fission
observed upon pharmacological inhibition of either PKD or SMS.
Inhibition of PKD has been reported not only to impair the
structure of the TGN but also of the cis-Golgi [48]. Thus the
effects of pharmacologic and siRNA-mediated inhibition of SMSs
on the cis compartment of the Golgi stack were assessed by
confocal microscopy using GPP130 as marker. In agreement with
the literature, inhibition of PKD disrupted the normal morphology
of the cis compartment promoting tubulation as also observed in
the case of the TGN (Figure 3, panel B versus A). Importantly,
inhibition of SMSs (either by D609 or by specific siRNA) exerted a
similar effect (Figure 3, panel D versus C and panels F or G
versus E). The morphological changes of either cis-o rtrans-Golgi
were more prominent in cells treated with D609 than in cells in
which individual down-regulation of SMS1 or SMS2 was induced
with siRNA. Since D609 inhibits both SMS1 and SMS2, it is
possible that the D609-mediated effect is the result of the additive
inhibition of both SMSs as compared to down-regulation of each
individual SMS with siRNA.
Collectively, these results indicate that both SMS1 and SMS2
activities are critical to retain the correct morphology of both cis-
Golgi and TGN, similarly to what was indirectly shown for PKD
[48]. The fact that inhibition of either SMS1 or SMS2 affected the
morphology not only of the trans- but also of the cis-Golgi could be
the result of the presence of different subpools of SMSs in the
different compartments of this organelle. Indeed, in HeLa cells,
different reports have localized SMS1 in both trans- and cis-Golgi
[8,24,49], and electron microscopy in these cells confirmed that
SMS1 is present in both compartments [50]. Importantly, the fact
that morphological alteration of both cis- and trans-Golgi was also
appreciated upon inhibition of PKD (Figures 1B and 3B)i si n
agreement with the potential role of PKD as down-stream target
for SMSs. The observations that down-regulation of SMSs affects
the morphology of the Golgi apparatus seem to disagree with
published data showing that down-regulation of SMS1 did not
significantly alter the distribution of alpha-mannosidase II [24].
On the other hand, it is possible that this difference might be due
to the fact that in the present study the Golgi morphology was
studied using endogenous markers (TGN46 and 38 for trans-Golgi
and GPP130 for cis-Golgi) whereas the published report used an
over-expression system which might have masked more subtle
changes. Support for a role of SMSs in maintenance of the Golgi
structure indirectly comes from experiments involving the vesicle-
associated membrane protein-associated proteins, VAPs. In fact,
down-regulation of the VAPs, which regulate the binding of
CERT to the ER for ceramide loading destined to SM synthesis,
caused significant alteration of Golgi morphology [51].
Effect of SMS1 or SMS2 siRNA on VSVG trafficking
Since PKD is a known regulator of fission of vesicles leaving the
TGN en route to the plasma membrane, and we observed that
SMSs are also important enzymes regulating Golgi morphology,
we wanted to test whether inhibition of SMS would affect protein
transport from the TGN to the plasma membrane. To this aim,
the effect of siRNA-mediated down-regulation of SMSs on
trafficking of the VSVG protein tagged with the Green
Fluorescent Protein (VSVG-GFP) was studied. A temperature
sensitive mutant was employed for these studies. Under the non-
permissive temperature of 40uC, the mutant VSVG-GFP
reversibly misfolds and is retained in the ER (Figure S1) [42].
Thus, in order to synchronize the trafficking of the protein, after
transfection and expression of VSVG-GFP at 37uC, the cells were
shifted to 40uC for five and half hours (Figure S1). Once the
trafficking of the mutant VSVG-GFP was synchronized, the cells
Figure 2. SMS1 or SMS2 inhibition modulates the TGN
organization. HeLa cells were transfected using Oligofectamine
TM
with 148 ng of scrambled siRNA (SCR, 2A), siRNA targeting SMS1
(SMS1.4 siRNA, 2B) or SMS2 (SMS2.3 siRNA, 2C). After 48 hours, cells
were fixed and processed for indirect Immunofluorescence with anti
TGN 46 (Trans Golgi marker) rabbit polyclonal antibodies and stained
with anti rabbit Alexa FluorH 488-conjugated secondary antibodies
(green). Confocal images were captured and processed using an LSM
510 META. Images are representatives of at least three independent
experiments. Dashed boxes outline the areas that were magnified.
doi:10.1371/journal.pone.0023644.g002
Role of SMSs in Protein Trafficking and Secretion
PLoS ONE | www.plosone.org 5 September 2011 | Volume 6 | Issue 9 | e23644were shifted to 32uC (temperature at which VSVG-GFP folds
correctly and exits the ER en-route to the Golgi apparatus [42]).
After 30 minutes at 32uC, VSVG-GFP reached the Golgi complex
(Figure S1) and within 60 minutes, it reproducibly reached the
plasma membrane (Figure S1). Beyond 60 minutes, endocytosis
of VSVG-GFP was observed in agreement with previous studies
Figure 3. SMS inhibition affects cis Golgi. HeLa cells were treated with DMSO (control for PKD inhibitor) (1A) or water (control for SMS inhibitor)
(1C), and 20 mM of PKD inhibitor (1B) or 30 mg/ml of SMS inhibitor D609 (1D). Alternatively, HeLa cells were transfected using Oligofectamine
TM with
148 ng of scrambled siRNA (SCR, 2E), siRNA targeting SMS1 (SMS1.4 siRNA, 2F) or SMS2 (SMS2.3 siRNA, 2G). After 4 hours of pharmacological
inhibition or 48 hours of siRNA treatment, cells were fixed and were processed for indirect immunofluorescence with anti GPP130 (cis Golgi marker)
rabbit polyclonal antibodies and stained with anti rabbit Alexa FluorH 488-conjugated secondary antibodies (green). Confocal images were captured
and processed using LSM 510 META. Images are representatives of at least three independent experiments.
doi:10.1371/journal.pone.0023644.g003
Figure 4. SMS1 and SMS2 regulate protein trafficking from the TGN to the plasma membrane. HeLa cells were treated with
Oligofectamine
TM transfection reagent alone (CT), 148 ng scrambled control siRNA (SCR siRNA), or siRNA targeting SMS1 (SMS1.3 siRNA or SMS1.4
siRNA) or SMS2 (SMS2.2 siRNA or SMS2.3 siRNA) for 48 hours. Cells were then transfected with VSVG-GFP by Lipofectamine 2000. After 16 hours of
incubation at 37uC, medium was replaced by DMEM containing 10% FBS and 0.1 M HEPES pH 7.4, and plates were shifted to 40uC for five and half
hours. After incubation, the medium was replaced by DMEM containing 10% FBS, 0.1 M HEPES pH 7.4 and 100 mg/ml of cyclohexamide, and the
plates were shifted to 32uC for 1 hour. Cells were fixed and were processed for indirect immunofluorescence with anti VSVG mouse monoclonal
antibodies (8G5F11) and stained with anti rabbit Alexa Fluor-555-conjugated secondary antibodies. Confocal images for VSVG-GFP (green) and
plasma membrane VSVG (red) were captured. Two representative images (A and B) for each experimental sample are presented. Images are
representatives of at least three independent experiments.
doi:10.1371/journal.pone.0023644.g004
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832/13 was measured by radioimmunoassay. The cells were treated with SMS pharmacological inhibitor, D609 (30 mg/ml and 50 mg/ml) or PKD
inhibitor CID755673 (20 mM and 40 mM) at 8 mM glucose for 2 hours. Media and cells were collected separately and insulin levels were determined in
each portion. Total insulin content was calculated as cellular plus secreted insulin, and secreted insulin was calculated as percent versus total. Since
the percent of secretion in basal conditions (3 mM glucose) was variable, final representation of secreted insulin is given as fold increase relative to
insulin secreted in basal conditions (3 mM glucose). The values are representative of at least 4 independent experiments. A p value,0.05 was
considered significant and is indicated by: * versus 3 mM glucose; # versus 8 mM glucose; and $ versus 8 mM glucose DMSO.
doi:10.1371/journal.pone.0023644.g005
Figure 6. Pharmacological inhibition of SMS causes extensive tubulation of cis Golgi and TGN in INS-1 cells. INS-1 cells were treated
with DMSO and water (control), and 20 mM of PKD inhibitor or 30 mg/ml of SMS inhibitor D609. After 4 hours of incubation, cells were fixed and
processed for indirect Immunofluorescence with rat anti TGN 38 (TGN marker) mouse monoclonal antibodies and anti mouse Alexa FluorH555-
conjugated secondary antibodies (red), and anti GPP130 (cis Golgi marker) rabbit polyclonal antibodies and anti rabbit Alexa FluorH 488-conjugated
secondary antibodies (green). Confocal images were captured and processed using LSM 510 META. Colocalization in 3D images was achieved using
velocity 3 software (improvision). Images are representatives of at least two independent experiments.
doi:10.1371/journal.pone.0023644.g006
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selected for the subsequent studies of the role of SMSs on the
trafficking of VSVG-GFP to the plasma membrane.
For down-regulation of SMSs, cells were treated with SCR,
SMS1 or SMS2 siRNA or Oligofectamine
TM alone (control) (two
different siRNA sequences for each SMS were used) and after
48 hours, cells were transfected with mutant VSVG-GFP and
incubated overnight at 37uC. After shifting the cells at 40uC for
five and half hours, they were incubated for 60 minutes at 32uC.
As shown in Figure 4 (CT and SCR siRNA, upper panels),
cells treated with transfection reagent (no siRNA; CT) or cells
treated with scrambled siRNA (SCR siRNA) showed significant
localization of VSVG-GFP at the plasma membrane. In order to
specifically visualize the VSVG pool present at the plasma
membrane, indirect immunofluorescence using an antibody that
specifically recognizes an extracellular epitope of VSVG (mAb
8G5F11) was employed. Non-permeabilized CT and SCR siRNA
cells were stained with the 8G5F11 antibody and showed a clear
plasma membrane localization of VSVG (Figure 4, CT and
SCR siRNA, lower panels). However, when cells were treated
with either SMS1 and to a lesser extent with SMS2 siRNA, VSVG
localization to the plasma membrane after 60 minutes incubation
at 32uC was critically impaired (Figure 4, SMS1.3 siRNA,
SMS1.4 siRNA, SMS2.2 siRNA, SMS2.3 siRNA). VSVG-
GFP in SMS1 and SMS2 down-regulated cells reached the plasma
membrane after approximately 80 to 90 minutes at 32uC when
control cells had already endocytosed it (data not shown). Thus
our results suggest that down-regulation of SMSs significantly
slows down (but does not completely block) the trafficking of
VSVG-GFP from the Golgi to the plasma membrane, and they
demonstrate that both SMS1 and SMS2 activities are important
for transport of protein/cargo from the Golgi complex to the
plasma membrane.
Role of SMS on insulin secretion
In order to further test the involvement of SMSs in regulation of
processes that are controlled by PKD at the TGN, the effect of
inhibition of SMSs on secretion of insulin was determined. In fact,
it was recently shown by Sumara and colleagues [48], that
inhibition of PKD impaired insulin secretion in rat INS-1 cells.
Thus the effect of pharmacological inhibition of SMSs on glucose-
induced insulin secretion by INS-1 was determined. Inhibition of
PKD by CID755673 was used as positive control. As shown in
Figure 5, an increase of insulin secretion was observed when
control cells (3 mM glucose) were stimulated with an higher
concentration of glucose (8 mM) demonstrating the expected
Figure 7. Down-regulation of SMS1 and SMS2 in Rat INS-1 (832/13) cells. SMSs were downregulated by specific siRNAs. Rat INS-1 cells were
either treated with a concentration of 50 nM of each individual siRNA sequence or with a combination of 50 nM of each siRNA sequence targeting
SMS1 (SMS1.1+SMS1.2 siRNAs) or SMS2 (SMS2.1+SMS2.2 siRNAs) for 47 hours. In the latter case, 100 nM SCR siRNA was used as control (SCR siRNA
mix). Cells were collected at 47 hours, total RNA was extracted, and RT-PCR was performed using specific primers for SMS1 or SMS2 and b-actin. The
RT-PCR results were analyzed using Q-GeneH software, and expressed as fold change versus the respective SCR controls. Panel (A) represents
expression of SMS1 and panel (B) represents expression of SMS2. The values are representative of at least 3 independent experiments. A p value,0.05
was considered significant and is indicated by: * versus SCR siRNA and # versus SCR siRNA mix.
doi:10.1371/journal.pone.0023644.g007
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expected dose dependent decrease of glucose-stimulated insulin
secretion was observed when PKD was inhibited (20 mM and
40 mM of CID755673), confirming the published involvement of
PKD in this process. Importantly, inhibition of SMS was also
found to significantly dose dependently repress insulin secretion in
response to glucose stimulation, demonstrating the ability of SMS
activity to regulate secretion of endogenous cargo.
In order to make sure that the mechanism of regulation of
insulin secretion by PKD and SMS was the same in INS-1 as in
HeLa cells, the effect of inhibition of PKD and SMS on the
morphology of the Golgi complex in INS-1 cells was determined.
For this, mouse monoclonal antibodies against rat TGN38 and
rabbit polyclonal antibodies against rat GPP130 were employed as
TGN and cis-Golgi markers, respectively (Figure 6). INS-1 cells
were co-stained after treatment with the PKD inhibitor,
CID755673 (20 mM) or the SMSs inhibitor, D609 (30 mg/ml).
Similarly to HeLa cells, INS-1 cells treated with either the PKD or
SMS inhibitor showed tubular structure of the TGN and cis-Golgi,
which was best appreciated using the velocity 3 (Improvision)
software for three-dimensional representation.
In order to rule out off-target effects of D609, the effect of
siRNA-mediated down-regulation of SMS1 and SMS2 on insulin
secretion was also determined. Thus two siRNA targeting
sequences for rat SMS1 or SMS2 each were tested individually
or in combination on their effectiveness in repress gene expression
(Figure 7). As shown in Figure 7A, treatment with a 50:50
combination of the two siRNA sequences targeting SMS1 resulted
in a more effective down-regulation of this gene compared to each
sequence used individually, therefore the combination of two
siRNA sequences was used to determine the effect of SMS1 or
SMS2 on insulin secretion. Importantly, the siRNA sequences
targeting either SMS did not significantly affect the expression of
the other SMS. As shown in Figure 8, down-regulation of either
SMS induced a significant reduction of glucose stimulated insulin
secretion similar to that observed upon pharmacological inhibi-
tion. The less prominent stimulation of insulin secretion induced
by 8 mM glucose (a little over 2 fold) in this case as compared to
that reported in Figure 5 (,7 fold) might be due to the lower
sensitivity of the ELISA method (used in this case) as compared to
the RIA assay used for Figure 5.
To the best of our knowledge, this is the first evidence of the
involvement of SMS in insulin secretion potentially through a
PKD mediated mechanism. Based on these results, it is possible
that one of the phenotypes of SMS1 or SMS2 knock-out mice
could be a defect in glucose metabolism due to impaired insulin
secretion. This hypothesis is indirectly supported by the observa-
tion that in Drosophila, loss of a functional CERT caused
increased glucose levels which could be due in part by impaired
secretion of drosophila insulin like peptides (DILP) [52,53]. While
this paper was under revision, a manuscript reporting a defect in
insulin secretion in SMS1 KO mice was published [54]. This is an
exciting observation that strengthens our results by confirming the
involvement of SMS1 in this process. Based on our results, we
propose that loss of SMS1 impairs PKD-mediated insulin secretion
in these mice, and that impairment of this pathway contributes to
their phenotype.
In conclusion, in this study we provide the first direct evidence
for a role of both SMS1 and SMS2 as regulators of protein
trafficking and secretion from the Golgi apparatus. In this report
we identify insulin as one of the protein cargos regulated by SMSs
activity. On the other hand, one important standing question is
how generalized is the effect exerted by modulation of SMS1 or
SMS2 on secretion. Perhaps this could depend upon the level of
activity of these proteins in different tissues. Interestingly, in a
parallel study, we found that SMS1 and SMS2 regulate
extracellular killing of the fungus Cryptococcus neoformans by
neutrophils [55] by regulating the presence/activity of an
antifungal factor in the medium. Since we found that modulation
of PKD in the neutrophil model has an effect similar to that
Figure 8. Down-regulation of SMS1 or SMS2 significantly reduces insulin secretion in Rat INS-1 (832/13) cells. Insulin secretion in
response to 3 and 8 mM glucose in INS-1 derived clone 832/13 was measured by ELISA. Cells transfected with SCR siRNA mix were incubated in the
presence of 3 mM or 8 mM glucose whereas cells transfected with SMS1 siRNAs mix or SMS2 siRNAs mix were incubated in the presence of 8 mM
glucose for 2 hours. Media and cells were collected separately and insulin levels were determined in each portion. Total insulin content was
calculated as cellular plus secreted insulin, and secreted insulin was calculated as percent versus total. Since the percent of secretion in basal
conditions (SCR siRNA mix 3 mM glucose) was variable, final representation of secreted insulin is given as fold change versus insulin secreted in basal
conditions (3 mM glucose). The values are representative of at least 3 independent experiments. A p value,0.05 was considered significant and is
indicated by: * versus SCR siRNA mix 3 mM glucose and # versus SCR siRNA mix 8 mM glucose.
doi:10.1371/journal.pone.0023644.g008
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regulate the secretion of microbial antifungal factors in a PKD-
dependent manner.
Finally, another important standing question is the existence of
more targets for DAG produced at the Golgi by SMS1 and/or
SMS2. In fact, in addition to PKD, DAG targets and activates
other proteins containing C1 domains such as classical and novel
protein kinase Cs (PKCs), Diacylglycerol Kinase, RasGRPs,
Chimaerins, and Munc13s [56]. Among these, PKCd, PKCg
and Munc13 have been all described to translocate to the Golgi
apparatus making them potential target candidates for Golgi
SMSs [18,36,45,57,58,59]. Most interestingly, PKCd has also
been recently linked to glucose stimulated insulin secretion [60]
and, in the course of preliminary experimentation, we found that
stimulation of SMS activity at the Golgi promoted translocation of
PKCd to this organelle, making this particular PKC an additional
potential target involved in the regulation of SMS-mediated
insulin secretion.
Supporting Information
Figure S1 Optimization of a cellular system for protein
transport and secretion. HeLa cells were transfected with
VSVG3-GFP using Lipofectamine 2000. After overnight incuba-
tion, medium was replaced with DMEM containing 10% FBS and
0.1 M HEPES pH 7.4. Plates were shifted to 40uC and incubated
for five and half hours, and some were then fixed (A). After
incubation, medium was changed to DMEM containing 10%
FBS, 0.1 M HEPES pH 7.4 and 100 mg/ml of cyclohexamide,
and the cells were shifted to 32uC for up to 70 minutes. Cells were
fixed at 30 min (B), 35 min (C), 40 min (D), 45 min (E), 50 min
(F), 55 min (G), 60 min (H), 65 min (I) and 70 min (J) and
analyzed by confocal microscopy. Images are representatives of at
least three independent experiments.
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